Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001382 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT00001382: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00001382 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 75 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001382, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
This trial will evaluate, in patients with metastatic prostate cancer, the tolerability, toxicities, efficacy, and immunologic effects of repeated vaccinations with a recombinant vaccinia virus that contains the Prostate Specific Antigen gene (PROSTVAC).
Interventions
- BIOLOGICAL PROSTVAC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 1994-03 |
| Est. Completion | 2000-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001382
The ClinicalTrials.gov registry entry for NCT00001382 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PROSTVAC is the first listed.
NCT00001382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001382 about?
NCT00001382 is a clinical study titled "A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate". This trial will evaluate, in patients with metastatic prostate cancer, the tolerability, toxicities, efficacy, and immunologic effects of repeated vaccinations with a recombinant vaccinia virus that contains the Prostate Specific Antigen gene (PROSTVAC).
What is the current status of trial NCT00001382?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 1994-03. Estimated completion is 2000-03.
What interventions are being tested in trial NCT00001382?
The interventions under investigation include: PROSTVAC (BIOLOGICAL).
Who is sponsoring clinical trial NCT00001382?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.